Integrity Alliance LLC. Increases Stock Position in Abbott Laboratories $ABT

Key Points

• Integrity Alliance LLC significantly increased its holdings in Abbott Laboratories by 582.8% in Q1, acquiring 12,635 additional shares, bringing their total to 14,803 shares worth approximately $1.964 million.
• Abbott Laboratories reported Q2 earnings of $1.26 per share, matching analyst estimates, with revenue of $11.14 billion, which exceeded expectations and marked a 7.4% year-over-year increase.
• The company recently declared a quarterly dividend of $0.59 per share, resulting in an annualized yield of 1.8%, and has a dividend payout ratio of 29.57%.

Integrity Alliance LLC. raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 582.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,803 shares of the healthcare product maker's stock after purchasing an additional 12,635 shares during the period. Integrity Alliance LLC.'s holdings in Abbott Laboratories were worth $1,964,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ABT. Brighton Jones LLC grew its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. Bank Pictet & Cie Europe AG grew its holdings in Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after purchasing an additional 2,774 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Abbott Laboratories by 6.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 168,417 shares of the healthcare product maker's stock valued at $19,050,000 after purchasing an additional 10,933 shares during the period. Occudo Quantitative Strategies LP acquired a new position in Abbott Laboratories during the fourth quarter valued at approximately $457,000. Finally, Northwest Quadrant Wealth Management LLC boosted its stake in Abbott Laboratories by 8.9% in the 4th quarter. Northwest Quadrant Wealth Management LLC now owns 2,422 shares of the healthcare product maker's stock worth $274,000 after purchasing an additional 198 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

ABT stock traded up $1.27 during trading on Friday, reaching $133.92. 5,700,290 shares of the company were exchanged, compared to its average volume of 4,674,658. The company has a 50-day moving average of $130.41 and a two-hundred day moving average of $131.32. The company has a market capitalization of $233.08 billion, a price-to-earnings ratio of 16.78, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same period in the prior year, the company earned $1.14 EPS. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.46% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Raymond James Financial reduced their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price target for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Evercore ISI increased their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Finally, Mizuho increased their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.